Health Technology · Pharmaceuticals: Other · NSE: CIPLA · data 2026-10-09
Cipla Ltd
Health check: Average (5.7/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,301
Market cap
₹1,05,427 cr
P/E
31.2
P/B
—
ROE
11.8%
ROCE
14.5%
Debt / equity
0.02
Dividend yield
1.00%
1-year return
-13.8%
52-week high
₹1,673
52-week low
₹1,165.7
Operating margin
14.4%
Growth
| Revenue (last 12 months) | ₹28,324 cr |
| Net profit (last 12 months) | ₹3,371 cr |
| Sales growth, 3 years (yearly) | 7.3% |
| Profit growth, 3 years (yearly) | 11.5% |
Similar companies
Aurobindo Pharma Ltd (AUROPHARMA) · Lupin Limited (LUPIN) · Granules India Limited (GRANULES) · Sudeep Pharma Limited (SUDEEPPHRM) · Amrutanjan Health Care Limited (AMRUTANJAN)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open CIPLA in NSE Scanner →